Close Menu

molecular imaging

The company is beginning a multi-site Phase II trial designed to establish that its approach can identify patients who will respond to immuno-oncology drugs.

The deal with AstraZeneca follows a licensing agreement signed earlier this year with Memorial Sloan Kettering Cancer Center also covering radionuclide PARP inhibitor IP.